- Home
- IBRX vs ALVO Comparison
IBRX vs ALVO Comparison
Compare IBRX & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- ALVO
- Stock Information
- Founded
- IBRX 2014
- ALVO 2013
- Country
- IBRX United States
- ALVO Luxembourg
- Employees
- IBRX N/A
- ALVO N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- ALVO Biotechnology: Pharmaceutical Preparations
- Sector
- IBRX Health Care
- ALVO Health Care
- Exchange
- IBRX Nasdaq
- ALVO Nasdaq
- Market Cap
- IBRX 2.3B
- ALVO 2.5B
- IPO Year
- IBRX N/A
- ALVO N/A
- Fundamental
- Price
- IBRX $2.81
- ALVO $8.52
- Analyst Decision
- IBRX Strong Buy
- ALVO Buy
- Analyst Count
- IBRX 5
- ALVO 1
- Target Price
- IBRX $11.40
- ALVO $18.00
- AVG Volume (30 Days)
- IBRX 7.3M
- ALVO 177.8K
- Earning Date
- IBRX 08-11-2025
- ALVO 08-14-2025
- Dividend Yield
- IBRX N/A
- ALVO N/A
- EPS Growth
- IBRX N/A
- ALVO N/A
- EPS
- IBRX N/A
- ALVO 0.34
- Revenue
- IBRX $31,222,000.00
- ALVO $587,890,000.00
- Revenue This Year
- IBRX $567.98
- ALVO $35.07
- Revenue Next Year
- IBRX $160.56
- ALVO $44.61
- P/E Ratio
- IBRX N/A
- ALVO $25.14
- Revenue Growth
- IBRX 10238.41
- ALVO 413.92
- 52 Week Low
- IBRX $1.83
- ALVO $7.35
- 52 Week High
- IBRX $7.48
- ALVO $13.70
- Technical
- Relative Strength Index (RSI)
- IBRX 51.33
- ALVO 33.95
- Support Level
- IBRX $2.68
- ALVO $8.86
- Resistance Level
- IBRX $3.00
- ALVO $9.26
- Average True Range (ATR)
- IBRX 0.16
- ALVO 0.27
- MACD
- IBRX -0.00
- ALVO -0.05
- Stochastic Oscillator
- IBRX 62.00
- ALVO 1.99
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.